Cholangiocarcinoma (Bile Duct Cancer): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Cholangiocarcinoma (CCA) is a malignant tumor arising from the epithelial cells (cholangiocytes) lining the biliary tract. It is classified anatomically as intrahepatic CCA (iCCA, approximately 20% of cases, arising within the liver parenchyma), perihilar CCA (pCCA or Klatskin tumor, approximately 50%, arising at the bifurcation of the right and left hepatic ducts), or distal extrahepatic CCA (dCCA, approximately 30%, in the common bile duct below the cystic duct). CCA represents approximately 3% of all gastrointestinal cancers globally, with rising incidence of iCCA worldwide. The majority of patients present with locally advanced or metastatic disease, as symptoms are often insidious and late. The recent demonstration that comprehensive molecular profiling reveals actionable alterations (FGFR2 fusions in approximately 15% of iCCA, IDH1 mutations in approximately 15% of iCCA) has fundamentally transformed the treatment paradigm, enabling precision oncology approaches in a substantial minority of patients.

Primary sclerosing cholangitis (PSC) confers a 10-15% lifetime CCA risk in Western countries and is the leading biliary risk condition. Liver flukes Opisthorchis viverrini and Clonorchis sinensis are major CCA risk factors in Southeast Asia and account for the dramatically higher CCA incidence in Thailand, Laos, and adjacent regions. Other risk factors: liver cirrhosis from any etiology (HBV, HCV, alcohol, NAFLD), biliary stones, congenital biliary malformations (choledochal cysts — type I and IV carry highest CCA risk), and NAFLD-associated metabolic syndrome. Key molecular alterations in iCCA: FGFR2 fusions/rearrangements (approximately 15%, targetable with pemigatinib or futibatinib); IDH1 mutations (approximately 15%, targetable with ivosidenib); KRAS mutations (approximately 25%, currently non-targetable); TP53 alterations; ARID1A mutations; BRCA1/2 mutations; HER2 amplification; NTRK fusions; RET fusions; MSI-high (approximately 2%); and high TMB. NGS at diagnosis is now mandatory for all CCA patients.

Perihilar and distal CCA: painless obstructive jaundice — progressive yellowing of the skin and sclera, dark urine (bilirubinuria), pale or clay-colored stools, and pruritus (from bile salt deposition) — is the cardinal presenting symptom, occurring in over 80% of patients. Charcot's triad (fever, right upper quadrant pain, and jaundice) signals biliary infection complicating the obstruction (cholangitis), a potentially life-threatening complication requiring urgent biliary drainage. Unintentional weight loss, anorexia, and fatigue reflect the metabolic burden of advanced cancer. Intrahepatic CCA: often entirely asymptomatic and detected incidentally on imaging performed for another indication; when symptomatic, presents with right upper quadrant pain or fullness, constitutional symptoms, and occasionally jaundice from bilobar duct invasion. Serum CA 19-9 is elevated above 100 U/mL in approximately 75% of CCA cases, though it is non-specific; CEA is elevated in approximately 50%.

Imaging: MRI with MRCP (magnetic resonance cholangiopancreatography) provides the most comprehensive assessment of biliary anatomy, tumor extent, vascular involvement, and regional lymph node status. CT thorax, abdomen, and pelvis for staging. Tissue diagnosis for perihilar/distal CCA: ERCP with brush cytology (sensitivity 40-70%; FISH for polysomy improves sensitivity to 60-80%); cholangioscopy (SpyGlass DS) with directed biopsies achieves diagnostic sensitivity over 85%. Intrahepatic CCA: CT-guided percutaneous core biopsy. Mandatory comprehensive NGS molecular profiling panel: FGFR2 fusions/rearrangements, IDH1/2 mutations, KRAS, NRAS, BRAF, NTRK, RET, HER2 amplification, MSI/MMR, and TMB — all potentially actionable alterations. PET-CT improves N and M staging. Portal vein embolization (PVE) augments future liver remnant volume (target FLR >30-40%) before major hepatic resection.

Resectable iCCA: major hepatic resection (right or left hepatectomy, possibly with caudate lobe) with mandatory R0 negative margins; adjuvant capecitabine for 24 weeks (BILCAP trial). Resectable perihilar CCA: hepatectomy with extrahepatic bile duct resection and bilioenteric anastomosis (right or left hepatectomy with caudate lobe); resection margins are frequently positive, requiring adjuvant radiotherapy. Resectable distal CCA: pancreaticoduodenectomy (Whipple procedure). Liver transplantation for selected unresectable perihilar CCA (Mayo Clinic criteria: ≤3 cm, no mets, neoadjuvant chemoradiation, ≤6 months waitlist): 5-year OS approximately 65-70%. Biliary drainage by ERCP (biliary stent) or PTC for obstructive jaundice relief. First-line advanced/metastatic CCA: gemcitabine plus cisplatin plus durvalumab (TOPAZ-1 trial) — median OS 12.8 months; gemcitabine plus cisplatin plus pembrolizumab (KEYNOTE-966) as an alternative. Second-line molecularly targeted therapies: pemigatinib or futibatinib (FGFR2 fusion+); ivosidenib (IDH1+); pembrolizumab (MSI-H); larotrectinib/entrectinib (NTRK+); neratinib or trastuzumab deruxtecan (HER2+).

Prognosis for cholangiocarcinoma remains poor, with most patients presenting with unresectable or metastatic disease. For resectable intrahepatic CCA: 5-year OS after R0 hepatic resection is approximately 25-40%; positive resection margins (R1) reduce 5-year OS to 10-20%. Resectable perihilar CCA (Klatskin tumor): 5-year OS approximately 20-35% after hepatectomy with bile duct resection; R0 resection is achievable in only approximately 50-60% of attempted cases due to proximity to hepatic arterial and portal venous structures. Resectable distal CCA after Whipple procedure: 5-year OS approximately 25-35%. Liver transplantation for selected unresectable perihilar CCA meeting Mayo Clinic criteria (neoadjuvant chemoradiation plus transplant): 5-year OS approximately 65-70% — the best outcome for this specific group. Unresectable or metastatic CCA treated with gemcitabine-cisplatin-durvalumab (TOPAZ-1): median OS 12.8 months; 24-month OS rate 24.9% — substantially better than the 10.4% rate with chemotherapy alone. Second-line molecularly targeted therapies extend median OS: pemigatinib or futibatinib for FGFR2 fusion-positive; ivosidenib for IDH1-mutated tumors (ClarIDHy trial: median OS 10.3 versus 7.5 months). Without treatment, unresectable CCA carries a median OS of 4-6 months. Key prognostic factors include resection margin status, lymph node involvement, vascular invasion, hepatic reserve (Child-Pugh score), primary tumor anatomical subtype, and actionable molecular alterations (FGFR2 fusion and IDH1 mutation predict targeted therapy benefit). Long-term surveillance after resection includes CA 19-9 and CEA every 3 months, liver function tests, and CT or MRI every 6 months for 5 years, transitioning to annual imaging thereafter.

Primary prevention: eradication of liver fluke infection (Opisthorchis viverrini, Clonorchis sinensis) through safe food practices in endemic regions (avoiding raw freshwater fish) and mass praziquantel treatment programs significantly reduces CCA incidence in Southeast Asia. Hepatitis B vaccination prevents HBV-related cirrhosis and CCA. Treatment of chronic HBV and HCV with antivirals reduces cirrhosis progression and CCA risk. Minimizing alcohol consumption, preventing and treating NAFLD through weight management and metabolic syndrome control, and surgical management of choledochal cysts (prophylactic excision prevents up to 10-15% CCA risk) are additional primary prevention strategies. Secondary prevention (surveillance in high-risk groups): PSC patients should undergo annual MRCP and CA 19-9 measurement; any new biliary stricture, dominant stricture worsening, or rising CA 19-9 in PSC requires urgent cholangioscopically directed biopsy to exclude CCA. Choledochal cyst patients who have not undergone surgical excision require surveillance imaging.

Seek prompt medical evaluation — within days, not weeks — for: any new painless jaundice (yellow discoloration of skin and eyes); dark urine and pale stools; progressive right upper quadrant abdominal pain; fever with jaundice (Charcot's triad — this is a biliary emergency requiring same-day hospital assessment); unexplained weight loss exceeding 5% over 3 months; and any incidental liver mass found on imaging performed for another reason. Patients with known primary sclerosing cholangitis should attend their scheduled annual MRCP surveillance appointments and contact their gastroenterologist or hepatologist promptly if they develop worsening jaundice, new pruritus, or fever — these may herald malignant stricture development. All CCA patients should be referred to a specialist hepatobiliary center with multidisciplinary team (hepatobiliary surgeon, medical oncologist, interventional endoscopist, interventional radiologist) for comprehensive staging and treatment planning before any therapeutic decisions are made.